We further revealed that the combination of MEK2 inhibition by lycorine and BRAF inhibition by vemurafenib resulted in enhanced anti-cancer activity in CRC, providing evidence of the potential of targeted combination regimens for personalized therapy. The gene discussed is MAP2K2; the disease is cancer.